课题基金 / 基金详情

12-Lipoxygenase and Ischemic Brain Cell Death

12-Lipoxygenase and Ischemic Brain Cell Death
12-脂氧合酶和缺血性脑细胞死亡
批准号:
7404413
负责人:
KLAUS VAN LEYEN
金额:
$33.55万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2010-03-31

项目摘要

项目成果

KLAUS VAN LEYEN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lipoxygenases and cyclooxygenases are among the oxidative enzymes that contribute to the generation of reactive oxygen species (ROS) after stroke. While the cyclooxygenases COX-1 and COX-2 have been and are continuing to be extensively studied, little data is available on the contribution of lipoxygenases to ischemic brain cell death. Our preliminary results have shown that levels of 12-LOX, the major lipoxygenase isoform in mouse and rat brain, are elevated in a mouse model of focal ischemia, predominantly in neuronal cells of the cortex. 12-LOX knockout mice show significantly reduced infarction sizes, a finding that seems to be mimicked by treatment of wild-type mice with a 12-LOX inhibitor. In both rat primary neurons and a murine hippocampal cell line, we have confirmed and extended the findings of others that 12-LOX mediates oxidative stress-induced cell death, and neurons prepared from the 12-LOX knockout mice show enhanced resistance to this form of oxidative stress. We thus propose the following Specific Aims: 1. To investigate 12-LOX upregulation and changes in activity in mouse brain after ischemia with various times of reoxyenation and to correlate increased 12-LOX levels with the extent of brain damage; 2. To study the mechanisms by which 12-LOX contributes to the death of cultured neuronal cells, and to elucidate the degradative machinery responsible for executing cell death downstream of 12-LOX action; 3. To determine the consequences of inactivating 12-LOX by either genetic or pharmacological means on brain damage after focal ischemia in the mouse. With the knowledge gained from these studies we seek to establish 12-LOX as a novel therapeutic target in the treatment of stroke.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Neuroprotectant to Reduce Ischemic Injury
  • 批准号:
    10576568
  • 项目类别:
  • 资助金额:
    $40.84万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network
  • 批准号:
    10671991
  • 项目类别:
  • 资助金额:
    $33.85万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Development of human 12/15-lipoxygenase therapeutics for stroke
  • 批准号:
    9898504
  • 项目类别:
  • 资助金额:
    $66.96万
  • 财政年份:
    2018
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Development of human 12/15-lipoxygenase therapeutics for stroke
  • 批准号:
    9922389
  • 项目类别:
  • 资助金额:
    $66.15万
  • 财政年份:
    2018
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位: